Impact of bromocriptine-QR therapy on glycemic control and daily insulin requirement in type 2 diabetes mellitus subjects whose dysglycemia is poorly controlled on high-dose insulin: A pilot study

Journal of Diabetes Research

Volumn 2015, Issue , 2015, Pages

  Roe, Erin D ^a   Chamarthi, Bindu ^b   Raskin, Philip ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN GLARGINE; METFORMIN; ANTIDIABETIC AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DYSGLYCEMIA; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; INSULIN TREATMENT; MALE; MIDDLE AGED; MORNING DOSAGE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PILOT STUDY; PRIORITY JOURNAL; AGED; BLOOD; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; METABOLISM; TREATMENT OUTCOME;

ADULT; AGED; BLOOD GLUCOSE; BROMOCRIPTINE; DIABETES MELLITUS, TYPE 2; DOPAMINE AGONISTS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 84929352889     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2015/834903     Document Type: Article

References (53)

1. R. A. Defronzo, "From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus", Diabetes, vol. 58, no. 4, pp. 773-795, 2009.
2. E. Ferrannini, A. Gastaldelli, Y. Miyazaki, M. Matsuda, A. Mari, and R. A. DeFronzo, "β-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis", Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 1, pp. 493-500, 2005.
3. K. Khunti, M. Davies, A. Majeed, B. L. Thorsted, M. L. Wolden, and S. K. Paul, "Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study", Diabetes Care, vol. 38, no. 2, pp. 316-322, 2015.
4. S. R. Heller, P. Choudhary, C. Davies et al., "Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration", Diabetologia, vol. 50, no. 6, pp. 1140-1147, 2007.
5. E. C. McNay, J. A. Teske, C. M. Kotz et al., "Long-term, intermittent, insulin-induced hypoglycemia produces marked obesity without hyperphagia or insulin resistance: a model for weight gain with intensive insulin therapy", American Journal of Physiology-Endocrinology and Metabolism, vol. 304, no. 2, pp. E131-E138, 2013.
6. A. E. Pontiroli, L. Miele, and A. Morabito, "Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: Systematic review and meta-analysis", Diabetes, Obesity and Metabolism, vol. 13, no. 11, pp. 1008-1019, 2011.
7. D. Russell-Jones and R. Khan, "Insulin-associated weight gain in diabetes-causes, effects and coping strategies", Diabetes, Obesity and Metabolism, vol. 9, no. 6, pp. 799-812, 2007.
8. S. A. Ross, H. D. Tildesley, and J. Ashkenas, "Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes", Current Medical Research and Opinion, vol. 27, no. 3, pp. 13-20, 2011.
9. P. Hildebrandt, "Subcutaneous absorption of insulin in insulindependent diabetic patients. Influence of species, physicochemical properties of insulin and physiological factors", Danish Medical Bulletin, vol. 38, no. 4, pp. 337-346, 1991.
10. L. Heinemann, "Variability of insulin absorption and insulin action", Diabetes Technology and Therapeutics, vol. 4, no. 5, pp. 673-682, 2002.
11. C. Binder, T. Lauritzen, O. Faber, and S. Pramming, "Insulin pharmacokinetics", Diabetes Care, vol. 7, no. 2, pp. 188-199, 1984.
12. V. Mattoo, D. Eckland, M. Widel et al., "Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study", Clinical Therapeutics, vol. 27, no. 5, pp. 554-567, 2005.
13. J. A. Davidson, A. Perez, J. Zhang, and Pioglitazone 343 Study Group, "Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study", Diabetes, Obesity and Metabolism, vol. 8, no. 2, pp. 164-174, 2006.
14. B. Charbonnel, R. DeFronzo, J. Davidson et al., "Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19)", Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 5, pp. 2163-2171, 2010.
15. C. Clar, P. Royle, and N. Waugh, "Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis", PLoS ONE, vol. 4, no. 7, Article ID e6112, 2009.
16. D. M. Hartung, D. R. Touchette, N. C. Bultemeier, and D. G. Haxby, "Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based casecontrol study", Pharmacotherapy, vol. 25, no. 10, pp. 1329-1336, 2005.
17. P. S. Chaggar, S. M. Shaw, and S. G. Williams, "Thiazolidinediones and heart failure", Diabetes and Vascular Disease Research, vol. 6, no. 3, pp. 146-152, 2009.
18. T. D. Giles, A. B. Miller, U. Elkayam, M. Bhattacharya, and A. Perez, "Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction", Journal of Cardiac Failure, vol. 14, no. 6, pp. 445-452, 2008.
19. A. J. Scheen, "Combined thiazolidinedione-insulin therapy: should we be concerned about safety?" Drug Safety, vol. 27, no. 12, pp. 841-856, 2004.
20. Actos (pioglitazone hydrochloride) prescribing information, http://www.accessdata.fda.gov/drugsatfda docs/label/2011/021073s043s044lbl.pdf, http://www.actos.com/pi.pdf.
21. J. M. Gaziano, A. H. Cincotta, C. M. O'Connor et al., "Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes", Diabetes Care, vol. 33, no. 7, pp. 1503-1508, 2010.
22. J. M. Gaziano, A. H. Cincotta, A. Vinik, L. Blonde, N. Bohannon, and R. Scranton, "Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects", Journal of the American Heart Association, vol. 1, no. 5, Article ID e002279, 2012.
23. A. I. Vinik, A. H. Cincotta, R. E. Scranton, N. Bohannon, M. Ezrokhi, and J. M. Gaziano, "Effect of Bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents", Endocrine Practice, vol. 18, no. 6, pp. 931-943, 2012.
24. R. Scranton and A. Cincotta, "Bromocriptine-unique formulation of a dopamine agonist for the treatment of type 2 diabetes", Expert Opinion on Pharmacotherapy, vol. 11, no. 2, pp. 269-279, 2010.
25. H. Pijl, S. Ohashi, M. Matsuda et al., "Bromocriptine: a novel approach to the treatment of type 2 diabetes", Diabetes Care, vol. 23, no. 8, pp. 1154-1161, 2000.
26. M. Ezrokhi, S. Luo, Y. Trubitsyna, and A. H. Cincotta, "Weighted effects of bromocriptine treatment on glucose homeostasis during hyperglycemic versus euglycemic clamp conditions in insulin resistant hamsters: bromocriptine as a unique postprandial insulin sensitizer", Journal of Diabetes & Metabolism, vol. S2, no. 1, 2012.
27. M. C. Moore, M. Smith, B. Farmer, and A. D. Cherrington, "Timed daily bromocriptine mesylate (BC) administration improves glucose disposal in a canine diet-induced model of impaired glucose tolerance", Diabetologia, vol. 57, supplement 1, p. S350, 2014.
28. S. Luo, J. Luo, and A. H. Cincotta, "Suprachiasmatic nuclei monoamine metabolism of glucose tolerant versus intolerant hamsters", NeuroReport, vol. 10, no. 10, pp. 2073-2077, 1999.
29. S. Luo, J. Luo, A. H. Meier, and A. H. Cincotta, "Dopaminergic neurotoxin administration to the area of the suprachiasmatic nuclei induces insulin resistance", NeuroReport, vol. 8, no. 16, pp. 3495-3499, 1997.
30. M. Ezrokhi, S. Luo, Y. Trubitsyna, and A. H. Cincotta, "Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats", Diabetology & Metabolic Syndrome, vol. 6, article 104, 2014.
31. A. H. Cincotta, "Hypothalamic role in insulin resistance and insulin resistance syndrome", in Frontiers in Animal Diabetes Research, B. Hansen and E. Shafrir, Eds., pp. 271-312, Taylor & Francis, London, UK, 2002.
32. S. Luo, J. Luo, and A. H. Cincotta, "Chronic ventromedial hypothalamic infusion of norepinephrine and serotonin promotes insulin resistance and glucose intolerance", Neuroendocrinology, vol. 70, no. 6, pp. 460-465, 1999.
33. A. H. Cincotta, S. Luo, Y. Zhang et al., "Chronic infusion of norepinephrine into the VMH of normal rats induces the obese glucose-intolerant state", The American Journal of Physiology-Regulatory Integrative and Comparative Physiology, vol. 278, no. 2, pp. R435-R444, 2000.
34. S. Luo, M. Ezrokhi, Y. Trubitsyna, and A. H. Cincotta, "Intrahypothalamic circuitry regulating hypothalamic fuel sensing to induce insulin sensitivity or insulin resistance", Diabetologia, vol. 51, supplement 1, p. S59, 2008.
35. J. M. Monti and D. Monti, "The involvement of dopamine in the modulation of sleep and waking", Sleep Medicine Reviews, vol. 11, no. 2, pp. 113-133, 2007.
36. A. H. Cincotta, T. A. MacEachern, and A. H. Meier, "Bromocriptine redirects metabolism and prevents seasonal onset of obese hyperinsulinemic state in Syrian hamsters", The American Journal of Physiology-Endocrinology and Metabolism, vol. 264, no. 2, pp. E285-E293, 1993.
37. S. Luo, A. H. Meier, and A. H. Cincotta, "Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters", Neuroendocrinology, vol. 68, no. 1, pp. 1-10, 1998.
38. M. Ezrokhi, S. Luo, T. Trubitsyna, and A. H. Cincotta, "Synergism of dopamine agonist plus GLP-1 analog therapy on improvement of glucose intolerance in Syrian hamsters", Diabetes, vol. 60, supplement 1, article A445, 2011.
39. A. Pocai, T. K. T. Lam, S. Obici et al., "Restoration of hypothalamic lipid sensing normalizes energy and glucose homeostasis in overfed rats", Journal of Clinical Investigation, vol. 116, no. 4, pp. 1081-1091, 2006.
40. T. K. T. Lam, "Neuronal regulation of homeostasis by nutrient sensing", Nature Medicine, vol. 16, no. 4, pp. 392-395, 2010.
41. D. M. Breen, C. S. Yang, and T. K. T. Lam, "Gut-brain signalling: how lipids can trigger the gut", Diabetes/Metabolism Research and Reviews, vol. 27, no. 2, pp. 113-119, 2011.
42. S. D. Jordan, A. C. Könner, and J. C. Brüning, "Sensing the fuels: glucose and lipid signaling in the CNS controlling energy homeostasis", Cellular and Molecular Life Sciences, vol. 67, no. 19, pp. 3255-3273, 2010.
43. K. Morgan, S. Obici, and L. Rossetti, "Hypothalamic responses to long-chain fatty acids are nutritionally regulated", The Journal of Biological Chemistry, vol. 279, no. 30, pp. 31139-31148, 2004.
44. S. Luo, Y. Zhang, M. Ezrokhi, Y. Trubitsyna, and A. H. Cincotta, "High-fat feeding abolishes the insulin-sensitizing peak in circadian dopamine activity at the biological clock", Diabetes, vol. 63, supplement 1, p. A470, 2014.
45. S. Luo, Y. Liang, and A. H. Cincotta, "Intracerebroventricular administration of bromocriptine ameliorates the insulinresistant/glucose-intolerant state in hamsters", Neuroendocrinology, vol. 69, no. 3, pp. 160-166, 1999.
46. K. G. Bina and A. H. Cincotta, "Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropinreleasing hormone, body weight gain, and hyperglycemia in ob/ob mice", Neuroendocrinology, vol. 71, no. 1, pp. 68-78, 2000.
47. B. M. Geiger, M. Haburcak, N. M. Avena, M. C. Moyer, B. G. Hoebel, and E. N. Pothos, "Deficits of mesolimbic dopamine neurotransmission in rat dietary obesity", Neuroscience, vol. 159, no. 4, pp. 1193-1199, 2009.
48. A. G. Roseberry, T. Painter, G. P. Mark, and J. T. Williams, "Decreased vesicular somatodendritic dopamine stores in leptin-deficient mice", Journal of Neuroscience, vol. 27, no. 26, pp. 7021-7027, 2007.
49. J. F. Davis, A. L. Tracy, J. D. Schurdak et al., "Exposure to elevated levels of dietary fat attenuates psychostimulant reward and mesolimbic dopamine turnover in the rat", Behavioral Neuroscience, vol. 122, no. 6, pp. 1257-1263, 2008.
50. B. M. Geiger, G. G. Behr, L. E. Frank et al., "Evidence for defective mesolimbic dopamine exocytosis in obesity-prone rats", FASEB Journal, vol. 22, no. 8, pp. 2740-2746, 2008.
51. P. Rada, M. E. Bocarsly, J. R. Barson, B. G. Hoebel, and S. F. Leibowitz, "Reduced accumbens dopamine in Sprague-Dawley rats prone to overeating a fat-rich diet", Physiology and Behavior, vol. 101, no. 3, pp. 394-400, 2010.
52. N. D. Volkow, G.-J. Wang, F. Telang et al., "Low dopamine striatal D2 receptors are associated with prefrontal metabolism in obese subjects: possible contributing factors", NeuroImage, vol. 42, no. 4, pp. 1537-1543, 2008.
53. J. Mendoza and E. Challet, "Circadian insights into dopamine mechanisms", Neuroscience, vol. 282, pp. 230-242, 2014.